Potenza 1.34 mg/ml (SC Injection)

3 ml cartridge with device: ৳ 5,000.00

Medicine Details

Category Details
Generic Semaglutide
Company Aci limited

Indications

  • Adjunct to diet and exercise for type 2 diabetes mellitus
  • Reducing the risk of cardiovascular events in type 2 diabetes mellitus
  • Adjunct to a reduced calorie diet and increased physical activity for chronic weight management

Pharmacology

  • GLP-1 analogue with 94% sequence as human GLP-1
  • Reduces blood glucose in a glucose dependent manner
  • Stimulates insulin secretion and lowers glucagon secretion
  • Reduces body weight and body fat mass by reducing appetite

Dosage & Administration

  • Starter Dose of 3 mg once daily for 30 days
  • Maintenance Dose of 7 mg once daily
  • Additional Glycemic Control with 14 mg once daily
  • Subcutaneous injection in abdomen, thigh, or upper arm
  • Dosage adjustment for patients switching between tablet and injection
  • Dosage for obesity starting at 0.25 mg once weekly
  • Dose escalation and maintenance dose for obesity with subcutaneous injection

Interaction

  • Delays gastric emptying
  • Potential impact on rate of absorption of concomitantly administered oral medicinal products

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients

Side Effects

  • Hypoglycemia when used with insulin or sulfonylurea
  • Gastrointestinal disorders
  • Nausea
  • Diarrhea
  • Vomiting
  • Abdominal pain
  • Constipation
  • Allergic reactions
  • Injection site reactions
  • Lipodystrophy
  • Pruritus
  • Rash

Pregnancy & Lactation

  • Not to be used during pregnancy
  • Discontinue at least 2 months before planned pregnancy
  • Not to be used during breastfeeding

Precautions & Warnings

  • Not to be used in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
  • Discontinue if pancreatitis is suspected
  • Monitoring for patients with diabetic retinopathy
  • Safety and efficacy in children and adolescents not yet established
  • No dose adjustment based on age
  • No dose adjustment for renal impairment
  • Not recommended for end-stage renal disease
  • No dose adjustment for hepatic impairment
  • Caution in treating patients with hepatic impairment

Overdose Effects

  • Reported overdose up to 4 mg in a single dose and up to 4 mg in a week
  • Most commonly reported adverse reaction: nausea
  • No specific antidote for overdose
  • Supportive treatment for overdose symptoms
  • Dose adjustment when added to existing metformin and/or thiazolidinedione therapy
  • Consideration for reduction in the dose of sulfonylurea or insulin when added to existing therapy
  • Missed dose administration instructions

Therapeutic Class

  • GLP-1 receptor agonists

Storage Conditions

  • Store at 2°C to 8°C (in a refrigerator)
  • Do not freeze
  • Keep out of reach of children

Related Brands